Compare Sana Biotechnology Inc (SANA) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Weibo Corp — how do they compare? Sana Biotechnology Inc trades at $2.85 (market cap $836.71M), while Weibo Corp trades at $6.54 (market cap $1.56B). The key difference: Weibo Corp is the larger of the two by market cap, and Weibo Corp pays a 9.47% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 23 Days and Weibo Corp for 102 Days on average.
| SANA | WB | |
|---|---|---|
Market Cap | $836.71M | $1.56B |
Volume | 4,507,444 | 812,503 |
Sector | Health | Media |
52-Week High | $5.92 | $12.37 |
52-Week Low | $2.68 | $6.33 |
Typical Hold Time | 23 Days | 102 Days |
Enterprise Value | $749.96M | $786.69M |
Dividend Yield | — | 9.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.83, up 4.04% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue generation, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent investor conference presentations highlight ongoing business development activities.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA carries high risk due to pre-revenue status, negative cash flow, and shareholder litigation concerns. The stock's investment case hinges on successful clinical development and future commercialization of its engineered cell therapies, requiring careful risk assessment by investors.
Weibo (WB) trades at $6.55, up 1.08% with bearish technical indicators but attractive valuation metrics including a P/E of 5.32 and P/B of 0.4. The company reported Q2 2026 earnings beat with $449M net income in 2025, though recent quarters show mixed results. Cash flow trends show volatility with a $694M net outflow in 2024, while analyst sentiment remains divided with 40.9% buy ratings amid concerns about user growth stagnation.
WB presents as a deep-value opportunity with strong profitability margins but faces significant headwinds from declining user metrics and advertising challenges. The stock's low valuation multiples suggest potential upside if operational stability improves, though competitive pressures and China's regulatory environment remain key risks for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
